The basic mechanisms and clinical efficacy of primary androgen deprivation therapy (PADT), especially combined androgen blockade (CAB) for localized or locally advanced prostate cancer (PCa) have been outlined. An important point relates to which patients are suitable candidates for PADT.
Methods:
A retrospective review of the efficacy of PADT in 628 patients with localized or locally advanced PCa treated with PADT at seven institutions in Japan was carried out.
Results:
It was found that more than 30% of low- or intermediate-risk localized PCa patients could have their disease controlled over the long-term by PADT alone. Short-term or intermittent PADT could not be recommended because of the possibility of character change in the cancer cells as a result of incomplete androgen ablation.
Conclusion:
Algorithms are proposed for the treatment of localized PCa not only in low- and intermediate-risk groups, but also in the high-risk group. Future research directions are indicated.
Get full access to this article
View all access options for this article.
References
1.
HugginsC., HodgesC.Studies on prostate cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res, 1941; 1:293–297.
2.
LabrieF., CandasB., GomezJ.L., CusanL.Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology, 2002; 60:115–119.
3.
AkazaH., LabrieF., NamikiM.A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation. Jap J Cancer Chemother, 2007; 34:657–669 [In Japanese].
4.
MizokamiA., YehS.Y., ChangC.Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol, 1994; 8:77–88.
5.
MizokamiA., ChangC.Induction of translation by the 5′-untranslated region of human androgen receptor mRNA. J Biol Chem, 1994; 269:25655–25659.
6.
ChamberlainN.L., DriverE.D., MiesfeldR.L.The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl Acids Res, 1994; 22:3181–3186.
7.
FukagaiT., NamikiT.S., CarlileR.G., YoshidaH., NamikiM.Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int, 2006; 97:1190–1193.
8.
Abdel-WahabM., BerkeyB.A., KrishanA., O’BrienT., HammondE., RoachM.3rd, et al.Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol, 2006; 29:14–20.
9.
KlotzL., CorreiaA., ZhangW.The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis, 2005; 8:179–183.
10.
PlatzE.A., LeitzmannM.F., RifaiN., KantoffP.W., ChenY.C., StampferM.J., et al.Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev, 2005; 14:1262–1269.
11.
LabrieF., DupontA., BélangerA., St-ArnaudR., GiguèreM., LacourcièreY., et al.Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev, 1986; 7:67–74.
12.
MizokamiA., KohE., FujitaH., MaedaY., EgawaM., KoshidaK., et al.The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res, 2004; 64:765–771.
13.
LabrieF., DupontA., BélangerA., GiguèreM., LacoursièreY., EmondJ., et al.Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem, 1985; 23:833–841.
14.
MurphyW.M., SolowayM.S., BarrowsG.H.Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer, 1991; 68:821–828.
15.
SmithD.M., MurphyW.M.Histologic changes in prostatic carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer, 1994; 73:1472–1477.
16.
ArmasO.A., AprikianA.G., MelamedJ., Cordon-CardoC., CohenD.W., ErlandsonR., et al.Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol, 1994; 18:979–991.
17.
VailancourtL., TêtuB., FradetY., DupontA., GomezJ., CusanL., et al.Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. Am J Surg Pathol, 1996; 20:86–93.
18.
MaedaO., UsamiM.General Rule for Clinical and Pathological Studies on Prostate Cancer. 3rd edition.. Kanahara, Tokyo: Japanese Urological Association, the Japanese Society of Pathology; 2001.
19.
KitagawaY., KoshidaK., MizokamiA., KomatsuK., NakashimaS., MisakiT., et al.Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol, 2003; 10:377–382.
20.
SchulmanC.C., DebruyneF.M., ForsterG., SelvaggiF.P., ZlottaA.R., WitjesW.P.4-year-follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. Eur Urol, 2000; 38:706–713.
21.
Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol, 2005; 12:46–61.
22.
MaedaO.Option and indication for early stage prostate cancer. Jap J Cancer Chemother, 2003; 30:26–31 [In Japanese].
23.
AkazaH., HommaY., UsamiM., HiraoY., TsushimaT., OkadaK., et al.Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int, 2006; 98:573–579.
24.
EgawaM., MisakiT., ImaoT., YokoyamaO., FuseH., SuzukiK., et al.Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol, 2004; 11:304–309.
25.
UenoS., NamikiM., FukagaiT., EharaH., UsamiM., AkazaH.Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol, 2006; 13:1494–1500.
26.
D’AmicoA.V., WhittingtonR., MalkowiczS.B., SchultzD., BlankK., BroderickG.A., et al.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA, 1998; 280:969–974.
27.
JohanssonJ.E., AndrénO., AnderssonS.O., DickmanP.W., HolmbergL., MagnusonA., et al.Natural history of early, localized prostate cancer. JAMA, 2004; 291:2713–2719.
28.
LabrieF.Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 2002; 198:77–87.
29.
MengM.V., ElkinE.P., HarlanS.R., MehtaS.S., LubeckD.P., CarrollP.R.Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. J Urol, 2003; 170:2279–2283.
30.
TanakaN., HaraH., YamabeF., TakasugiK., KataokaK., OhiraN., et al.Investigation on prostate re-biopsy and high-sensitivity PSA of prostate cancer patients, receiving endocrine therapy. Jap J Urol, 2005; 96:196 [In Japanese].
MizokamiA., UenoS., FukagaiT., ItoK., EharaH., KinbaraH., et al.Global update on defining and treating high-risk localizing prostate cancer with leuprolin: an Asian perspective. BJU Int, 2007; 99(Suppl. 1):6–9discussion 17-8.
33.
KatoT., KomiyaA., SuzukiH., ImamotoT., UedaT., IchikawaT.Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. Int J Urol, 2007; 14:416–421.
34.
KorfageI.J., deKoningH.J., HabbemaD.F., SchröderF.H., Essink-BotM.L.Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy control ?. BJU Int, 2007; 99:801–806.
35.
SmithM.R., EasthamJ., GleasonD.M., ShashaD., TchekmedyianS., ZinnerN.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 2003; 169:2008–2012.
36.
Braga-BasariaM., DobsA.S., MullerD.C., CarducciM.A., JohnM., EganJ., et al.Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol, 2006; 24:3979–3983.
